The role of MRD in multiple myeloma

Over the last two decades, treatment approaches for multiple myeloma have significantly changed, and measurable residual disease (MRD) assessment is being increasingly recognized as a valuable tool to monitor patient response to therapy. Although there are several clinical trials incorporating MRD status as a clinical endpoint, its use in the real-world setting remains unclear.

In this podcast, you will hear from experts Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Mattia D’Agostino, MD, University of Turin, Turin, Italy, and Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, who discuss the prognostic role of MRD in multiple myeloma, the value of MRD-guided treatment, and clinical trials in this space.